Executives from CVS Health and Aetna sought to assure lawmakers that their US$69 billion merger would create value for consumers and not result in anti-competitive behavior. They spoke at a hearing before the House Judiciary Regulatory Reform, Commercial and Antitrust Law Subcommittee on Tuesday, February 27.
Despite raising concerns that the deal would be bad for consumers and the healthcare system, the AMA’s statement did not ask Congress or regulators to block the deal.
Full Content: Medpage Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Florida Attorney General Launches Investigation Into OpenAI and ChatGPT
Apr 9, 2026 by
CPI
Chainalysis Sees Stablecoins Becoming Core Global Payment Infrastructure
Apr 9, 2026 by
CPI
Meta Ramps Up AI Spending with New $21 Billion Cloud Agreement
Apr 9, 2026 by
CPI
StubHub to Pay $10 Million to Settle FTC Ticket Pricing Case
Apr 9, 2026 by
CPI
Apple Seeks International Help to Obtain Samsung Evidence in DOJ Antitrust Case
Apr 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers